Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Sarah Kammerer"'
Autor:
Anne Krüger-Genge, Susanne Köhler, Markus Laube, Vanessa Haileka, Sandy Lemm, Karolina Majchrzak, Sarah Kammerer, Christian Schulz, Joachim Storsberg, Jens Pietzsch, Jan-Heiner Küpper, Friedrich Jung
Publikováno v:
Cells, Vol 12, Iss 15, p 1965 (2023)
Cancer patients are at a very high risk of serious thrombotic events, often fatal. The causes discussed include the detachment of thrombogenic particles from tumor cells or the adverse effects of chemotherapeutic agents. Cytostatic agents can either
Externí odkaz:
https://doaj.org/article/83964bfc5dd142859c27ae12253ad052
Autor:
Susanne Steinbrecht, Jan Kiebist, Rosalie König, Markus Thiessen, Kai-Uwe Schmidtke, Sarah Kammerer, Jan-Heiner Küpper, Katrin Scheibner
Publikováno v:
AMB Express, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract Cyclophosphamide (CPA) represents a widely used anti-cancer prodrug that is converted by liver cytochrome P450 (CYP) enzymes into the primary metabolite 4-hydroxycyclophosphamide (4-OH-CPA), followed by non-enzymatic generation of the bioact
Externí odkaz:
https://doaj.org/article/02be8937c7c9421ca3f00981bdaa4085
Autor:
Dimitrios Vagiannis, Youssif Budagaga, Anselm Morell, Yu Zhang, Eva Novotná, Adam Skarka, Sarah Kammerer, Jan-Heiner Küpper, Ivo Hanke, Tomáš Rozkoš, Jakub Hofman
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 21, p 11936 (2021)
Tepotinib is a novel tyrosine kinase inhibitor recently approved for the treatment of non-small cell lung cancer (NSCLC). In this study, we evaluated the tepotinib’s potential to perpetrate pharmacokinetic drug interactions and modulate multidrug r
Externí odkaz:
https://doaj.org/article/0212eb51dc624676ad5bb0e9e6facdd1
Autor:
Sarah Kammerer
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 19, p 10214 (2021)
Drug-induced liver injury (DILI) is the major reason for failures in drug development and withdrawal of approved drugs from the market. Two-dimensional cultures of hepatocytes often fail to reliably predict DILI: hepatoma cell lines such as HepG2 do
Externí odkaz:
https://doaj.org/article/421647144b7944b9b1ff10551604a6d4
Publikováno v:
Life, Vol 11, Iss 2, p 91 (2021)
The application of cytostatic drugs or natural substances to inhibit cancer growth and progression is an important and evolving subject of cancer research. There has been a surge of interest in marine bioresources, particularly algae, as well as cyan
Externí odkaz:
https://doaj.org/article/66c4b312febc407da383a5d43ffb5681
Autor:
Nadine Katzenberger, S. Steinbrecht, Sarah Kammerer, Jan-Heiner Küpper, Nadine Pfeifer, Christian Schulz, Natalie Herzog
Publikováno v:
Toxicology Letters. 319:155-159
Novel HepG2 cell clones 1A2 C2 and 1A2 C7 were independently generated by lentiviral transduction to functionally overexpress cytochrome P450 1A2 (CYP1A2). We found similar and stable CYP1A2 transcript and protein levels in both cell clones leading t
Publikováno v:
Journal of Cellular Biotechnology. 5:55-64
Publikováno v:
Life
The application of cytostatic drugs or natural substances to inhibit cancer growth and progression is an important and evolving subject of cancer research. There has been a surge of interest in marine bioresources, particularly algae, as well as cyan
Autor:
Jan Kiebist, Sarah Kammerer, Katrin Scheibner, Rosalie König, Kai-Uwe Schmidtke, S. Steinbrecht, Markus Thiessen, Jan-Heiner Küpper
Publikováno v:
AMB Express, Vol 10, Iss 1, Pp 1-13 (2020)
AMB Express
AMB Express
Cyclophosphamide (CPA) represents a widely used anti-cancer prodrug that is converted by liver cytochrome P450 (CYP) enzymes into the primary metabolite 4-hydroxycyclophosphamide (4-OH-CPA), followed by non-enzymatic generation of the bioactive metab
Autor:
Dimitrios Vagiannis, Eva Novotna, Adam Skarka, Sarah Kammerer, Jan-Heiner Küpper, Si Chen, Lei Guo, Frantisek Staud, Jakub Hofman
Publikováno v:
Cancers
Cancers, Vol 12, Iss 813, p 813 (2020)
Cancers, Vol 12, Iss 813, p 813 (2020)
Ensartinib (X-396) is a promising tyrosine kinase inhibitor currently undergoing advanced clinical evaluation for the treatment of non-small cell lung cancer. In this work, we investigate possible interactions of this promising drug candidate with AT